

Award Number: DAMD17-03-1-0529

TITLE: Using RNA Interference to Reveal Genetic Vulnerabilities in Human Cancer Cells

PRINCIPLE INVESTIGATOR: Despina Siolas
Gregory Hannon, Ph.D.

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory
Cold Spring Harbor, NY 11724

REPORT DATE: July 2006

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE 01-07-2006			2. REPORT TYPE Annual Summary			3. DATES COVERED 1 Jul 2003 – 30 Jun 2006		
4. TITLE AND SUBTITLE Using RNA Interference to Reveal Genetic Vulnerabilities in Human Cancer Cells						5a. CONTRACT NUMBER		
						5b. GRANT NUMBER DAMD17-03-1-0529		
						5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Despina Siolas Gregory Hannon, Ph.D.						5d. PROJECT NUMBER		
						5e. TASK NUMBER		
						5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724						8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012						10. SPONSOR/MONITOR'S ACRONYM(S)		
						11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited								
13. SUPPLEMENTARY NOTES Original contains colored plates: ALL DTIC reproductions will be in black and white.								
14. ABSTRACT A major barrier to understanding breast cancer is the lack of comprehensive and systematic large scale studies that provide functional information about the entire genome. These insights can be obtained through RNAi (RNA interference) genetic studies. RNAi is a cellular process that regulates gene expression in a sequence specific manner. We have developed a library of plasmids expressing shRNAs that engage the endogenous RNAi pathway and produce mature siRNAs that efficiently target any gene of interest. We have generated more than 200,000 constructs that allow us to perform loss of function studies of almost every gene in the human genome. Furthermore, we have developed a microarray-based analytical platform that facilitates the study of thousands of genes concurrently in pools. We conducted a screen to detect resistance to anoikis (cell death triggered by loss of attachment to the extracellular matrix, ECM) in the MCF10A breast epithelial cell line. Our screen of 1,500 shRNAs resulted in identifying the well known tumor suppressor, Pten, as an attenuator of anoikis among other candidate genes. In addition, we have validated an in vitro anoikis assay as an approach to identify putative tumor suppressors involved in breast epithelial cell transformation.								
15. SUBJECT TERMS Cancer, RNAi, gene silencing								
16. SECURITY CLASSIFICATION OF:				UU	12	18. NUMBER OF PAGES		
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	19a. NAME OF RESPONSIBLE PERSON USAMRMC					
						19b. TELEPHONE NUMBER (include area code)		

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	6
Key Research Accomplishments.....	10
Reportable Outcomes.....	10
Conclusions.....	10
References.....	11

Introduction:

RNA interference (RNAi) is a conserved biological process in response to double-stranded RNA (dsRNA)¹. DsRNAs are processed into short interfering RNAs (siRNAs), about 22 nucleotides in length, by the RNase enzyme Dicer. The siRNAs are then incorporated into a silencing complex called RISC (RNA-induced silencing complex), which identifies and silences complementary messenger RNAs. The most well characterized source of endogenous triggers for the RNAi machinery are the microRNA genes^{2,3}. Numerous studies have demonstrated that, in animals, miRNAs are transcribed to generate long primary polyadenylated RNAs (pri-miRNAs)^{4,5}. Through mechanisms not yet fully understood, the pri-microRNA is recognized and cleaved at a specific site by the nuclear Microprocessor complex⁶⁻¹⁰ to produce a ~70-90 nucleotide microRNA precursor (pre-miRNA) which is exported to the cytoplasm^{11,12}. Only then is the pre-miRNA recognized by Dicer and cleaved to produce a mature microRNA. This probably involves recognition of the 2 nucleotide 3' overhang created by Drosha to focus Dicer cleavage at a single site ~22 nucleotides from the end of the hairpin¹³.

This process can be programmed experimentally in order to repress the expression of any chosen gene. We have constructed shRNA libraries (shRNA-mir) that uses our advanced understanding of miRNA biogenesis. ShRNA-mirs are modeled after endogenous miRNAs, specifically contained in the backbone of the primary miR-30 microRNA¹⁴. We have produced and sequence-verified more than 200,000 shRNAs covering almost all of the predicted genes in the mouse and human genomes¹⁵.

Our shRNA library can function in both individual cell based assays and pooled screens. We have linked a unique 60-nucleotide DNA barcode to each shRNA vector to allow us to follow the fate of shRNAs in populations of virally transduced cells. If, for example, a particular shRNA provided resistance to a growth inhibitor stimulus, then the representation of its associated barcode should be increased after treatment. If a given shRNA sensitized a population to a specific stress, then the relative abundance of its barcode should diminish after the stress. This is measured by hybridizing genomic PCR products containing the barcodes to custom microarrays that contain the complement of these sequences. One can assess cellular response to different treatments by comparing barcode representations of cell populations expressing known shRNA. The development of this highly efficient RNAi library together with the ability to screen

pools of genes, provide us with the unique opportunity to investigate the entire genome in loss of function studies to find relevant genes to any biological process.

Cancer is responsible for almost a quarter of the total annual number of deaths in the US. Among them, breast cancer presents the highest incidence in women¹⁶. To understand the tumorigenic process, it is imperative to identify and characterize the genes that provide tumor cells with the capabilities requisite for their initiation and progression. A major barrier to increasing our understanding of breast cancer is the lack of comprehensive and systematic large scale functional studies. We address this by conducting a genome-wide in vitro RNAi screen to find genes that promote hallmarks of transformation like resistance to apoptosis or uncontrolled proliferation¹⁷.

The best in vitro system to uncover genes involved in breast cancer would be one in which normal human mammary epithelial cells (HMEC) could be transformed by a single experimentally-induced genetic lesion. Several cell culture models of human cell transformation have been described in which primary human cells are first immortalized and then transformed by combinations of dominantly acting cellular and viral oncogenes¹⁸⁻²⁰. Immortalization is achieved by viral oncogenes that alter the genetic background of the primary cells mainly by blocking TP53 and RB. Then, transformation is promoted by an additional single genetic lesion. However, blocking of these major tumor suppressors introduces a great bias in the screen, as it may mask other potentially relevant genes that show epistatic interactions with them. Furthermore, viral protein may interfere with a large number of cellular components, making it difficult to define a limited number of genetic lesions that cooperate for transformation.

The MCF-10A cell line represents an alternative to these classic models of human cell transformation. MCF-10A is a spontaneously immortalized, but non-transformed, human mammary epithelial cell line²¹. These cells exhibit numerous features of normal breast epithelium, including lack of tumorigenicity in nude mice, lack of anchorage-independent growth, and dependence on growth factors and hormones for proliferation and survival²¹. Furthermore, these cells retain the ability to form arrested acini that recapitulate the structure found in in vivo mammary glandular epithelium. Genetically, MCF-10A has been extensively characterized. These cells have a deletion of the locus containing p16 and p14ARF^{21,22}, but more importantly, they maintain intact p53 and Rb loci and a stable karyotype (S. Muthuswamy


personal communication and our own unpublished results). I have collaborated with Jose Silva, a postdoc in our lab on developing RNAi screens. We looked for genes that enhance resistance to apoptosis is examined by inducing anoikis in MCF-10A. Anoikis is a natural mechanism used by monostratified epithelia for tissue morphogenesis and as a defense mechanism against abnormal proliferation that is generally lost in transformed cell. After detachment from the extracellular matrix (ECM), normal cells die by anoikis while tumor cells survive^{23,24}. Thus, the study of anoikis, a naturally occurring phenomenon in vivo using the MCF-10A cell line will provide us with a list of candidates with potential involvement in breast carcinogenesis. The most promising resulting genes will be further studied and their mechanism of action characterized. The data originated by these studies will increase our knowledge about breast tumorigenesis and may have an important impact on breast cancer therapy.

Body:

In mammalian cells, proliferation is the result of a highly complex signaling network. External and internal signals converge in every individual cell in order to maintain the tissue homeostasis and, as a final goal, the organism viability. Every cell integrates these control signals as a process to sense its environment and then decide whether to proliferate, arrest or die²⁵. This elaborate homeostasis control is universally disturbed in cancers, and it leads to unrestrained proliferation, resistance to programmed cell death or both¹⁷.

Using our pooled shRNA strategy, I assisted Jose Silva, a postdoc in our lab to perform a screen using a library of 1,500 shRNAs to monitor the acquisition of these tumor features for human normal breast epithelial cells. Cell death was induced by loss of attachment to the ECM. This process known as anoikis is widely used for the morphogenetic development of epithelial tissues. Cells that loose the contact with the ECM die by apoptosis, leaving an empty space that is used to remodel the organ. Additionally, anoikis is also a defense mechanism that has to be circumvented by epithelial tumor cells in order to grow out of their natural environment^{23,24}. To induce anoikis, mammary epithelial MCF-10A cells expressing the shRNA library were plated in conditions that do not allow them to form ECM. These cells are sensitive to loss of attachment and die after several days. However, the activity of specific shRNAs allows the cells to gain resistance and prolong survival (*Figure.1*). Before performing the screen, we reconstructed the

experiment to test whether we could enrich the survival population of our anoikis assay with a known clone of resistant cells. In order to obtain a clone resistant to anoikis, MCF-10A cells were transformed with an activated form of Ras (MCF-10A/Ras). MCF10A/Ras and MCF-10A wild type were mixed in a frequency of 1/1,500 and the anoikis screen was performed. After the completion of the anoikis screen the representation of the MCF-10A/Ras cells was analyzed by allele specific quantitative PCR (QPCR). This experiment revealed that MCF-10A/RAS cells were enriched around 50 fold in the population that survived anoikis (data not shown).



In addition, cells that had Pten knockdown were overrepresented in the population after anoikis stress (Figure.2). Interestingly, we also found that inhibition of Rb enhanced the cell death mediated by loss of attachment (Figure.2). It is important to mention that the screen was performed in triplicate, and that the st.dev. of the biological replicas was less than 30% for up to 80% of the hairpins.





Figure 2. Anoikis screen results. This graph shows the changes in the representation of 1,500 shRNAs after an anoikis assay of MCF-10A cells. The changes are quantified as the ratio

between the representation after anoikis assay (Ls) and normal conditions of growth (Ns) . The bold yellow line shows the average of this ratio for the population of shRNAs and the thin lines represent the different possible cut offs (1, 1.5 and 2 st. dev). Green bars are the st.dev. for every individual barcode among the biological replicas. The arrows indicate the position of different hairpins targetting Rb (blue) and Pten (red) before and after puromycin selection.

Additionally, it is worth mentioning that barcode specific QPCR analysis confirmed the microarray results (data not shown). When Pten and Rb stably knocked-down cells were studied, we found that in MCF-10A cells, RNAi of Pten increased survival to anoikis 3 fold, and that RNAi of Rb reduced survival 2 fold (*Figure.3A and B*).

The tumour-suppressor phosphatase with tensin homology (PTEN) has been identified as one of the most important negative regulators of the cell-survival signaling pathway. When PTEN is not functional, augmented PI3K activity constitutively activates survival signals increasing the resistance to cellular stress. Numerous types of tumors have been found carrying alterations in PTEN²⁶. Interestingly, Rb is another bona fide tumor suppressor that represses the expression of the transcription factor E2F. Derepressed E2F induces the transition of genes required for cell cycle progression²⁷. Thus, it could be expected that suppression of Rb led to E2F downstream targets activation and induction of proliferation. However, E2F is also connected to apoptotic pathways by increasing the transcriptional level of caspases. Consequently, loss of Rb sensitizes



cells to apoptosis when exposed to stress stimuli²⁸. Together these results validate our shRNA pool screen strategy as an adequate platform to analyze RNAi screens. They also validate our anoikis assay as an approach to identify tumor suppressors genes in breast cancer.

Key Research Accomplishments:

- Assisting in the construction and validation of second-generation shRNA (shRNAmir) expression libraries that have been designed based on an increased knowledge of RNAi biochemistry. We have generated large-scale arrayed, sequence-verified libraries comprising more than 140,000 shRNAmir expression plasmids, covering a substantial fraction of all predicted genes in the human and mouse genomes.
- A RNAi screen in MCF10A breast cancer cells identifying genes that are involved in apoptosis and growth arrest.

Reportable Outcomes:

Manuscripts:

Jose M. Silva, Mamie Z. Li, Ken Chang, Wei Ge, Michael C. Golding, Ricky Rickles, **Despina Siolas**, Guang Hu, Patrick J. Paddison, Michael R. Schlabach, Nihar Sheth, Jeff Bradshaw, Julia Burchard, Amit Kulkarni, Guy Cavet, Ravi Sachidanandam, W. Richard McCombie, Michele A. Cleary, Stephen J. Elledge, and Gregory J. Hannon. Second-Generation shRNA Libraries Covering the Mouse and Human Genomes. *Nature Genetics* 2005 Nov;37(11):1281-8.

Siolas, D., Lerner C., Burchard J., Ge W., Linsley PS., Paddison PJ., Hannon GJ., Cleary MA. (2005) Synthetic shRNAs as potent RNAi triggers. *Nature Biotechnology*. 23(2):227-31

Conclusions:

Using our shRNA pool strategy, I worked with Jose Silva, a postdoc in our lab to perform genome-wide RNAi in vitro screens and develop our microarray platform. One RNAi screen performed examined the acquisition of resistance to apoptosis and uncontrolled proliferation in normal human mammary epithelial cells (MCF-10A) upon gene suppression. We used an assay to detect resistance to anoikis (cell death triggered by loss of attachment to the extracellular matrix, ECM). Anoikis is a natural defense mechanism of monostratified epithelia against abnormal proliferation that is generally lost in transformed cells. Thus, normal cells die by anoikis when they become deattached from the ECM while tumor cells survive longer. Our screen of 1,500 shRNAs resulted in the identification of the well known tumor suppressor Pten as an attenuator of the anoikis effect.

References:

1. Hannon, G.J. RNA interference. *Nature* **418**, 244-51. (2002).
2. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* **116**, 281-97 (2004).
3. He, L. & Hannon, G.J. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* **5**, 522-31 (2004).
4. Lee, Y. et al. MicroRNA genes are transcribed by RNA polymerase II. *Embo J* **23**, 4051-60 (2004).
5. Cai, X., Hagedorn, C.H. & Cullen, B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. *RNA* **10**, 1957-66 (2004).
6. Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature* **425**, 415-9 (2003).
7. Denli, A.M., Tops, B.B., Plasterk, R.H., Ketting, R.F. & Hannon, G.J. Processing of primary microRNAs by the Microprocessor complex. *Nature* **432**, 231-5 (2004).
8. Landthaler, M., Yalcin, A. & Tuschl, T. The Human DiGeorge Syndrome Critical Region Gene 8 and Its D. melanogaster Homolog Are Required for miRNA Biogenesis. *Curr Biol* **14**, 2162-7 (2004).
9. Han, J. et al. The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev* **18**, 3016-27 (2004).
10. Gregory, R.I. et al. The Microprocessor complex mediates the genesis of microRNAs. *Nature* **432**, 235-40 (2004).
11. Yi, R., Qin, Y., Macara, I.G. & Cullen, B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. *Genes Dev* **17**, 3011-6 (2003). 21
12. Lund, E., Guttinger, S., Calado, A., Dahlberg, J.E. & Kutay, U. Nuclear export of microRNA precursors. *Science* **303**, 95-8 (2004).
13. Siolas, D. et al. Synthetic shRNAs as potent RNAi triggers. *Nat Biotechnol* **23**, 227-31 (2005).
14. Zeng, Y., Wagner, E.J., Cullen, B.R. 2002. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. *Mol. Cell* **9**, 1327–1333.
15. Silva, J.M., Li, M.Z., Chang, K., Ge, W., Golding, M.C., Rickles, R.J., Siolas, D., Hu, G., Paddison, P.J., Schlabach, M.R., Sheth, N., Bradshaw, J., Burchard, J., Kulkarni, A., Cavet, G., Sachidanandam, R., McCombie, W.R., Cleary, M.A., Elledge, S.J., Hannon, G.J. 2005. Second-generation shRNA libraries covering the mouse and human genomes. *Nature Genetics* **37**, 1281 – 1288.
16. American Cancer Society. Statistics for 2006.
17. [Hanahan, D., Weinberg, R.A.](#) 2000. The hallmarks of cancer. *Cell*. 100(1):57-70.
18. Elenbaas, L. Spirio, F. Koerner, M.D. Fleming, D.B. Zimonjic, J.L. Donaher, N.C. Popescu, W.C. Hahn R.A. Weinberg. 2001. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. *Genes Dev.* **15**, 50–65.
19. Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks, M.W., Weinberg, R.A. 1999. Creation of human tumour cells with defined genetic elements. *Nature* **400**, 464–468.
20. Zhao, J.J., Roberts, T.M., Hahn, W.C. 2004. Functional genetics and experimental models of human cancer. *Trends Mol. Med.* **10**, 344–350

21. Soule, H.D., Maloney, T.M., Wolman, S.R., Peterson, W.D., Brenz, R., McGrath, C.M., Russo, J., Pauley, R.J., Jones, R.F., Brooks, S.C. 1990. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. *Cancer Res.* 50, 6075–6086.
22. Debnath, J., Muthuswamy, S.K., Brugge, J.S. 2003. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods.* 30(3):256-68.
23. Grossmann, J. 2002. Molecular mechanisms of "detachment-induced apoptosis, Anoikis". *Apoptosis.* 7(3):247-60.
24. Frisch, S.M., Screaton, R.A. 2001. Anoikis mechanisms. *Curr. Opin. Cell Biol.* 13(5):555-62.
25. Lowe, S.W., Cepero, E., Evan, G. 2004. Intrinsic tumour suppression. *Nature.* 432:307-15.
26. Cully, M., You, H., Levine, A. J, Mak, T.W. 2006. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. *Nat. Rev. Cancer* 6:184-92.
27. Chau, B.N., Wang, J.Y. 2003. Coordinated regulation of life and death by RB. *Nat. Rev. Cancer* 3:130-8.
28. Nahle, Z., Polakoff, J., Davuluri, R.V., McCurrach, M.E., Jacobson, M.D., Narita, M., Zhang, M.Q., Lazebnik, Y., Bar-Sagi, D., Lowe, S.W. 2002. Direct coupling of the cell cycle and cell death machinery by E2F. *Nat. Cell Biol.* 4:859-64.